Analyst calls Orphazyme's 300 percent value jump "strange and noteworthy"

Danish biotech company Orphazyme experienced a dramatic value increase on the US stock exchange on Thursday, with trading of the share suspended 20 times. Nordnet analyst Per Hansen calls the increase illogical.
Photo: BRENDAN MCDERMID/REUTERS / X90143
Photo: BRENDAN MCDERMID/REUTERS / X90143
BY RITZAU, TRANSLATED BY CATHERINE BRETT

On Thursday, Danish biotech company Orphazyme experienced a dramatic value jump on the US stock exchange.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading